A vaccine trial will undergo soon to vaccinate against getting COVID-19.
New vaccines will always have issues that need to be straightened out over time and use. Even if it does work it will be another year before we see it offered to everyone.
According to The Daily Mail:
A second US company is poised to begin a small safety test of a vaccine against the new coronavirus.
Inovio Pharmaceuticals said Monday that it has Food and Drug Administration (FDA) permission for the study in 40 healthy volunteers in Philadelphia and Kansas City, Missouri, and plans to give its first dose of the experimental vaccine the same day.
The study, funded by the Bill and Melinda Gates Foundation, is a first step to see if the vaccine appears safe enough for larger tests needed to prove whether it will protect. Even if the research goes well, it is expected to take over a year before any vaccine could be widely available.
Last month, the first safety test in people of a different vaccine candidate began in Seattle. It was developed by the National Institutes of Health (NIH) and Moderna Inc.
Numerous other research groups are attempting to make vaccines against COVID-19 using a variety of different methods in hopes at least one will offer protection.
Inovio's approach is what's called a DNA vaccine, made using a section of the virus's genetic code packaged inside a piece of synthetic DNA.
The company says it has already begun recruiting volunteers for its study in each of the two locations.
Testing will take place at the University of Pennsylvania's Perelman School of Medicine and the Center for Pharmaceutical Research in Kansas City.
Each volunteer will get two doses of the experimental vaccine, given four weeks apart.
'We anticipate rapid enrollment of this initial study,' said Dr Pablo Tebas, an infectious disease specialist and professor of Medicine at the Hospital of the University of Pennsylvania who is the principal investigator for that location.
'There has been tremendous interest in this vaccine among people who want to do what they can to help protect the greater public from this pandemic as soon as possible.'
